Clinical Trials Browser

Resectable Biliary Tract Cancer × durvalumab × Gastrointestinal × Clear all

NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Phase 2 Unknown

Gastrointestinal

Resectable Biliary Tract Cancer